RxDoctor Payments Data

Thavalinh Sphabmixay, MD

Family Medicine · Atwater, CANPI 1841445277

Payments from drug & device makers

$3,051in general payments, 2019–2025

Across 171 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$366
  • GSK$273
  • Johnson & Johnson$238
  • Lilly USA, LLC$209
  • Pfizer$209
  • Novo Nordisk$189
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,039100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,051 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$351,940
Medicare patients
665
Services billed
5,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$97,418
OzempicSemaglutide101$93,186
EliquisApixaban82$80,101
FarxigaDapagliflozin Propanediol81$77,894
NuplazidPimavanserin Tartrate12$56,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$30,185
RybelsusSemaglutide13$27,176
XareltoRivaroxaban13$22,283
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$17,147
MyrbetriqMirabegron20$12,741
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,113
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen309$9,219
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,905
Atorvastatin Calcium517$6,975
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$6,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$189$120,362114 claims
Boehringer IngelheimJardiance, Stiolto Respimat$11$104,36783 claims
AstraZenecaFarxiga, Breztri Aerosphere$132$88,00799 claims
PfizerEliquis, Paxlovid$209$81,48596 claims
Acadia Pharmaceuticals IncNuplazid$20$56,03812 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$273$41,88263 claims
Johnson & JohnsonXarelto$238$22,28313 claims
Sanofi-aventis U.S. LLCLantus$184$2,67032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Atwater

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →